Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details an increase in share interests for specific individuals following the re-investment of dividends paid on January 3, 2013. The transaction price was 1,360.969 pence per ordinary share. Specific increases included:
- Sir Andrew Witty: 2,470 shares
- Lady C Witty (Connected Person): 1,873 shares
- Mr I W Whyte: 113 shares
- Mrs V A Whyte: No change reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director shareholdings in compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Confirm the dividend reinvestment price of 1,360.969 pence per share.
- Verify the specific share count increases for Sir Andrew Witty and connected persons.
- Note that this filing contains no operational or financial performance data for the period.